

Treatments for mild COVID-19: Cochrane evidence

**Sarah Chapman and Selena Ryan-Vig for *Evidently Cochrane* 16
March 2022, updated 06 February 2024**

References

Antibiotics (Azithromycin)

Burch J and Tort S. For adults with asymptomatic or mild COVID-19, what are the effects of azithromycin? Cochrane Library, Cochrane Clinical Answers, 26 October 2021. Web. 27 October 2021. <https://doi.org/10.1002/cca.3870>

Popp M, Stegemann M, Riemer M, Metzendorf M-I, Romero CS, Mikolajewska A, Kranke P, Meybohm P, Skoetz N, Weibel S. Antibiotics for the treatment of COVID-19. Cochrane Database of Systematic Reviews 2021, Issue 10. Art. No.: CD015025. DOI: 10.1002/14651858.CD015025. Accessed 27 October 2021. <https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015025/full>

Antiplatelets

Fischer A-L, Messer S, Riera R, Martimbianco ALC, Stegemann M, Estcourt LJ, Weibel S, Monsef I, Andreas M, Pacheco RL, Skoetz N. Antiplatelet agents for the treatment of adults with COVID-19. Cochrane Database of Systematic Reviews 2023, Issue 7. Art. No.: CD015078. DOI: 10.1002/14651858.CD015078. <https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015078/full>

Colchicine

Burch J and Tort S. What are the effects of colchicine for treatment of asymptomatic or mild COVID-19? Cochrane Library, Cochrane Clinical Answers, 19 October 2021. Web 20 October 2021. <https://doi.org/10.1002/cca.3848>

Mikolajewska A, Fischer A-L, Piechotta V, Mueller A, Metzendorf M-I, Becker M, Dorando E, Pacheco RL, Martimbianco ALC, Riera R, Skoetz N, Stegemann M. Colchicine for the treatment of COVID-19. Cochrane Database of Systematic Reviews 2021, Issue 10. Art. No.: CD015045. DOI: 10.1002/14651858.CD015045. Accessed 18 October 2021. <https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015045/full>

Convalescent plasma

Chapman S. Convalescent plasma to treat people with COVID-19: the evidence so far. Evidently Cochrane blog, 15 May 2020 (last updated 03 February 2023) Web. 23 February 2023. Available from: <https://www.evidentlycochrane.net/convalescent-plasma/>

Iannizzi C, Chai KL, Piechotta V, Valk SJ, Kimber C, Monsef I, Wood EM, Lamikanra AA, Roberts DJ, McQuilten Z, So-Osman C, Jindal A, Cryns N, Estcourt LJ, Kreuzberger N, Skoetz N. Convalescent plasma for people with COVID-19: a living systematic review. *Cochrane Database of Systematic Reviews* 2023, Issue 2. Art. No.: CD013600. DOI: 10.1002/14651858.CD013600.pub5. Accessed 03 February 2023. <https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013600.pub5/full>

Favipiravir

Korula P, Alexander H, John JSara, Kirubakaran R, Singh B, Tharyan P, Rupali P. Favipiravir for treating COVID-19. *Cochrane Database of Systematic Reviews* 2024, Issue 2. Art. No.: CD015219. DOI: 10.1002/14651858.CD015219.pub2. Accessed 06 February 2024. <https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015219.pub2/full>

Inhaled corticosteroids

COVID-NMA. Pharmacologic treatments for COVID-19 patients: Corticosteroids (14 comparisons). Web. 9 March 2022. https://covid-nma.com/living_data/index.php?treatment1=corticosteroids&submit=Validate-comparisons_div

National Institute for Health and Care Excellence. Section 7.3 Corticosteroids. In: *COVID-19 rapid guideline: managing COVID-19*. London: National Institute for Health and Care Excellence; February 2022. (**NICE NG191**). [Issued March 2021; last updated 23 February 2022]. Version 21.1; published 3 March 2022. Available from: <https://app.magicapp.org/#/guideline/L4Qb5n/section/n3e9gj>

National Institute for Health and Care Excellence. Therapeutics for COVID-19: Section 7.1 Corticosteroids. In: *COVID—19 rapid guideline: managing COVID-19*. London: National Institute for Health and Care Excellence; August 2021. (**NICE NG191**). [Issued 23 March 2021; last updated 10 August 2021]. Available from: <https://www.nice.org.uk/guidance/ng191/resources/fully-accessible-version-of-the-guideline-pdf-pdf-51035553326>

Tort S and Ciapponi A. For people with mild COVID-19, what are the effects of inhaled corticosteroids? *Cochrane Library, Cochrane Clinical Answers*, 11 March 2022. Web. 15 March 2022. <https://www.cochranelibrary.com/cca/doi/10.1002/cca.3956/full>

Wagner C, Griesel M, Mikolajewska A, Mueller A, Nothacker M, Kley K, Metzendorf M-I, Fischer A-L, Kopp M, Stegemann M, Skoetz N, Fichtner F. Systemic corticosteroids for the treatment of COVID-19. *Cochrane Database of Systematic Reviews* 2021, Issue 8. Art. No.: CD014963. DOI: 10.1002/14651858.CD014963. Accessed 16 August 2021. <https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014963/full>

World Health Organization. *Corticosteroids for COVID-19: Living guidance*. Geneva: World Health Organization; 2 September 2020. Available from: <https://apps.who.int/iris/rest/bitstreams/1299344/retrieve>

World Health Organization. Therapeutics and COVID-19: living guideline. Geneva: World Health Organization; 3 March 2022. Available from: <https://apps.who.int/iris/bitstream/handle/10665/352285/WHO-2019-nCoV-therapeutics-2022.2-eng.pdf>

Ivermectin

Burch J, Tort S, Bunt C. “Does administering post-exposure ivermectin prevent COVID-19 infection in asymptomatic close household contacts?” Cochrane Library, Cochrane Clinical Answers, 29 July 2021. Web. 13 August 2021. <https://www.cochranelibrary.com/cca/doi/10.1002/cca.3775/full>

Burch J, Tort S, Bunt C. “For adults with mild or moderate symptomatic COVID-19, what are the effects of ivermectin?” Cochrane Library, Cochrane Clinical Answers, 29 July 2021. Web. 13 August 2021. <https://www.cochranelibrary.com/cca/doi/10.1002/cca.3774/full>

Cochrane. Ivermectin for preventing and treating COVID-19. Cochrane.org, 28 July 2021. Web. 28 July 2021. <https://www.cochrane.org/news/ivermectin-preventing-and-treating-covid-19>

Popp M. Ivermectin for preventing and treating COVID-19 Cochrane Library, Cochrane podcasts, 17 August 2021. Web. 10 March 2022. <https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015017.pub2/related-content/podcast/73270/>

Popp M, Reis S, Schießer S, Hausinger Rllona, Stegemann M, Metzendorf M-I, Kranke P, Meybohm P, Skoetz N, Weibel S. Ivermectin for preventing and treating COVID-19. Cochrane Database of Systematic Reviews 2022, Issue 6. Art. No.: CD015017. DOI: 10.1002/14651858.CD015017.pub3. Accessed 24 June 2022. <https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015017.pub3/full>

Monoclonal antibodies

Burch J and Tort. For adults with asymptomatic or mild COVID-19, what are the effects of SARS-CoV-2-neutralising monoclonal antibodies (alone or combined)? Cochrane Library, Cochrane Clinical Answers, 07 September 2021. Web. 14 October 2021. <https://www.cochranelibrary.com/cca/doi/10.1002/cca.3724/full>

Kreuzberger N, Hirsch C, Chai KL, Tomlinson E, Khosravi Z, Popp M, Neidhardt M, Piechotta V, Salomon S, Valk SJ, Monsef I, Schmaderer C, Wood EM, So-Osman C, Roberts DJ, McQuilten Z, Estcourt LJ, Skoetz N. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database of Systematic Reviews 2021, Issue 9. Art. No.: CD013825. DOI: 10.1002/14651858.CD013825.pub2. Accessed 14 October 2021. <https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013825.pub2/full>

Kreuzberger N. Are laboratory-made, COVID-19-specific monoclonal antibodies an effective treatment for COVID-19? Cochrane Library, Cochrane Podcasts, 22 September 2021. Web. 14 October 2021.

<https://www.cochrane.org/podcasts/10.1002/14651858.CD013825.pub2>

Nirmatrelvir/ritonavir

Reis S, Metzendorf M-I, Kuehn R, Popp M, Gagyor I, Kranke P, Meybohm P, Skoetz N, Weibel S. **Nirmatrelvir combined with ritonavir for preventing and treating COVID-19**. *Cochrane Database of Systematic Reviews* 2022, Issue 9. Art. No.: CD015395. DOI:

10.1002/14651858.CD015395.pub2

<https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015395.pub2/full>

Remdesivir

Grundeis F, Ansems K, Dahms K, Thieme V, Metzendorf M-I, Skoetz N, Benstoem C, Mikolajewska A, Griesel M, Fichtner F, Stegemann M. Remdesivir for the treatment of COVID-19. *Cochrane Database of Systematic Reviews* 2023, Issue 1. Art. No.: CD014962. DOI: 10.1002/14651858.CD014962.pub2. Accessed 26 January 2023.

<https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014962.pub2/full>

National Institute for Health and Care Excellence. Therapeutics for COVID-19: Section 7.1.2 Remdesivir. In: *COVID—19 rapid guideline: Managing COVID-19*. (Version v27.7). 04 January 2023. Web. 26 January 2023.

<https://www.nice.org.uk/guidance/ng191/resources/covid19-rapid-guideline-managing-covid19-pdf-51035553326>

Vitamin D supplementation

Piechotta V and Stroehlein JK. Is vitamin D an effective and safe treatment for COVID-19?

Cochrane Library, Cochrane podcasts, 15 July 2021. Web. 15 March 2022.

<https://www.cochrane.org/podcasts/10.1002/14651858.CD015043>

Stroehlein JK, Wallqvist J, Iannizzi C, Mikolajewska A, Metzendorf M-I, Benstoem C, Meybohm P, Becker M, Skoetz N, Stegemann M, Piechotta V. Vitamin D supplementation for the treatment of COVID-19: a living systematic review. *Cochrane Database of Systematic Reviews* 2021, Issue 5. Art. No.: CD015043. DOI: 10.1002/14651858.CD015043. Accessed 06 August 2021.

<https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015043/full>

Further reading:

Chapman S and Ryan-Vig S. Treatments for moderate to severe COVID-19: Cochrane evidence. Evidently Cochrane blog, 16 March 2022. Web. 16 March 2022. Available from:

<https://www.evidentlycochrane.net/treatments-for-moderate-to-severe-covid-19-cochrane-evidence/>

